Implementation of Biomarkers

€1M–€4M||3-5 years

12:00 noon; full proposal deadline 23 February 2027

Last seen in a scan/import: 18 Oct 2026.

Catalog updated: 18 Oct 2026.

These timestamps are not source verification. Confirm the current deadline and your eligibility on the funder’s call page before applying.

Closed for now. See which open grants match your research. 30s, no email. See my matches →

The KWF Implementation of Biomarkers programme funds multidisciplinary consortia €1-€4 million over 3-5 years to embed clinically validated biomarkers (technology readiness level 7-9) into routine oncology care across the Netherlands. Consortia must include at least four parties (academic, clinical, industry, and patient representatives), a mandatory health technology assessment specialist, and a patient oversight committee. This call is unique for prioritising implementation science and real-world integration over discovery research.

Details

Funder	KWF
Budget	€1M–€4M
Duration	3-5 years
Consortium	Required — multidisciplinary consortium with minimum 4 participating parties, which may include private partners, supported by a project manager
Application	2-stage: pre-proposal (deadline 20 October 2026) → full proposal (deadline 23 February 2027, by invitation) → interviews May 2027 → funding decision June 2027
TRL	7-9
Frequency	Annual
Next round	2027-08
Eligible countries	NL

Eligibility & scope

For phase III studies with a clinical-grade biomarker and/or projects implementing clinical-grade biomarkers into routine oncology care (TRL7-9) in the Netherlands. Requires HTA specialist in team, patient perspective embedded, steering committee, and is restricted to Dutch research institutions; PhD candidates strongly discouraged on the project.

Who Should Apply

•Multidisciplinary consortia with minimum 4 participating organisations (academic, hospital, industry, patient advocates)
•Experienced researchers and clinicians (PhD candidates discouraged)
•Teams with a validated biomarker at TRL 7-9 ready for clinical implementation
•Applicants able to embed a health technology assessment specialist and patient steering committee
•Dutch institutions hosting the consortium lead

Key Dates

•Pre-proposal deadline 20 October 2026 (12:00 noon); full proposal deadline 23 February 2027 (12:00 noon)
•Two-stage: pre-proposal screening → full proposal and interview (May 2027) → funding decision June 2027
•Project duration 3-5 years

Tips for Applicants

✓Assemble your consortium and HTA specialist early; late additions weaken scoring and KWF may reject incomplete teams at pre-proposal triage.
✓The steering committee and patient representatives must be named and active from the pre-proposal stage; token inclusion fails the embedded patient perspective criterion.
✓Budget co-funding from industry or regional cancer networks; KWF favours risk-shared models and is more likely to fund if private-sector commitment is explicit.

Frequently Asked Questions

What is the budget for the KWF Implementation of Biomarkers call?

€1-€4 million per project over 3-5 years. Consortia are encouraged to seek co-funding from industry or other partners.

Who must be part of a consortium for the KWF Implementation of Biomarkers?

Minimum four parties including academic/clinical researchers, an HTA specialist, industry or implementation partners, and patient representatives. A KWF-approved steering committee is mandatory.

What is meant by TRL 7-9 in this call?

Technology Readiness Level 7-9 describes biomarkers that have been clinically validated and are ready for implementation into real-world healthcare settings, not early-stage research tools.

Is the KWF Implementation of Biomarkers call annual?

Yes, KWF runs this call annually with pre-proposal opens in late August and deadlines in October (pre-proposal) and February (full proposal).

Can PhD candidates lead a team on the KWF Implementation of Biomarkers?

PhD candidates are strongly discouraged; the call targets experienced researchers and clinicians.

cancer-biomarkersimplementation-sciencekwfconsortium-requiredhealth-technology-assessmenttranslational-oncologynetherlandsearly-stage-commercialisation